一名怀孕期糖尿病的孕妇患者报告了缩放和根植规划
Milda Chmieliauskaite1, Marie D Grosh2, Ali Syed3
1University of Washington Department of Oral Medicine School of Dentistry, Box 356370, 1959 NE Pacific Street, Seattle, WA 98195-6370, USA.
Dental clinics of North America
|September 15, 2023
概括
本案例研究讨论了在患有控制良好的妊娠糖尿病的孕妇中治疗I期牙周病的方法. 在局部麻醉下,牙科手术,包括剥皮和根平整,被认为是安全的.
科学领域:
- 产科和妇科 产科和妇科
- 牙周病学 牙周病学
- 内分泌学 在内分泌学.
背景情况:
- 孕期糖尿病 (GDM) 需要在怀孕期间进行谨慎的管理.
- 由于荷尔蒙的变化,牙周病的患病率在怀孕期间增加.
- 管理像GDM和牙周病这样的并发疾病会带来独特的临床挑战.
研究的目的:
- 举例来说,一个患有GDM的孕妇正在接受牙周治疗.
- 评估在怀孕期间在患有GDM的患者中进行缩放和根的安全性和可行性.
- 强调产科和牙科之间跨学科护理的重要性.
主要方法:
- 一份病例报告详细介绍了一名患有GDM和I期牙周病的孕妇患者.
- 牙科治疗包括在局部麻醉下使用血管收缩剂进行切除和根平整.
- 在整个治疗期间,对患者的血糖控制进行了监测.
主要成果:
- 患者的每日血糖水平保持在目标范围内.
- 没有观察到牙科治疗的不良事件或禁忌.
- 成功治疗了第一阶段的牙周病.
结论:
- 在怀孕期间,对于有良好控制的GDM患者,可以安全地进行缩放和根除.
- 在这种临床背景下,用血管收缩剂进行局部麻醉被认为是安全的.
- 有效的牙周病管理对于整体的孕产妇和胎儿健康至关重要.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Pathophysiology of Diabetes
980
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
980
Oral Hypoglycemic Agents: Biguanides and Glitazones
230
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
230
Dipeptidyl Peptidase 4 Inhibitors
211
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
211
Diabetes: Management and Pharmacotherapy
309
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
309
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
203
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
203


